Fulcrum Therapeutics, Inc. announced that Esther Rajavelu has resigned from her position as chief financial officer, effective April 21, 2023. Ms. Rajavelu will serve in a consulting role to ensure the continuity of the company's financial operations.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.395 USD | -4.09% | -5.58% | +9.04% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.04% | 479M | |
+64.15% | 62.59B | |
-2.09% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+12.48% | 26.21B | |
-22.05% | 19.09B | |
+3.74% | 13.08B | |
+25.60% | 12.26B | |
+27.19% | 12.05B |
- Stock Market
- Equities
- FULC Stock
- News Fulcrum Therapeutics, Inc.
- Fulcrum Therapeutics, Inc. Announces Resignation of Esther Rajavelu as Chief Financial Officer, Effective April 21, 2023